Alex Herrera, MD
Enriched profileChief, Division of Lymphoma; Associate Professor, Department of Hematology & Hematopoietic Cell Transplantation · City of Hope National Medical Center
Alex Herrera is Chief, Division of Lymphoma; Associate Professor, Department of Hematology & Hematopoietic Cell Transplantation at City of Hope National Medical Center. OpenAlex indexes 564 publications with 11,961 citations (h-index 47); ClinicalTrials.gov lists 14 registered studies with this person as an investigator.
Data verified 14 Aug 2026
Overview
Updated 14 Oct 2026
Alex F. Herrera, MD, is Chief, Division of Lymphoma at City of Hope National Medical Center (City of Hope Comprehensive Cancer Center), Duarte, CA. The public record shows 564 publications with 11,961 citations (h-index 47), centered on Hematology. It also documents an investigator role on 14 registered clinical trials, industry payments reported by 27 companies, 3 NIH-funded awards (2018–2026).
- Most recent indexed publication: 2026 · Blood
- Top research focus: Hematology
- 14 registered trials on ClinicalTrials.gov
- Open Payments reporting from 27 companies
Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 65 in PubMed.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingPublic positions
sourced statements on record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →pubmed.ncbi.nlm.nih.gov ↗
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 14 Oct 2026
Listed as an investigator on 14 registered studies on ClinicalTrials.gov. The most recent:
Industry payments
Updated 14 Oct 2026
27 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year20256 payments
- E.R. Squibb & Sons, L.L.C.Program year20252 payments
- PFIZER INC.Program year20253 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
100%Short-acting sulfonamides100%Sulfamethoxazole-Trimethoprim100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 14 Oct 2026
3 NIH research awards on record, funded 2018–2026 per NIH RePORTER. The latest:
- Clinical Protocol and Data Management
Beckman Research Institute/city of Hope
FY2026$222,906P30CA033572 - Leading NCI Clinical Trials Network research nationally and at the City of Hope Comprehensive Cancer Center
Beckman Research Institute/city of Hope
FY2026$208,103R50CA285409 - Leading NCI Clinical Trials Network research nationally and at the City of Hope Comprehensive Cancer Center
Beckman Research Institute/city of Hope
FY2025$208,103R50CA285409
Publications
Updated 14 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Polatuzumab Vedotin Combined With R-ICE (PolaR-ICE) as Second-Line Therapy in Diffuse Large B-Cell Lymphoma.
American journal of hematology
Clinical Trial2026 - Pembrolizumab and pralatrexate for relapsed or refractory peripheral T-cell lymphomas.
British journal of haematology
Article2026
Online presence
Updated 14 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/alex-herrera-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
Mentions by others
where others cite or feature them- LinkedIn
linkedin.com/posts/city-of-hope_watch-alex-herrera-md-discuss-results-activity-7071229127407632384-yTN7
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - Apple Podcasts
podcasts.apple.com/us/podcast/beyond-the-asco-plenary-alex-herreras-story/id1534737585
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →podcasts.apple.com ↗ - X / Twitter
x.com/cityofhope/status/1847359281978556760
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →x.com ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗ - X / Twitter
@cityofhope (X/Twitter) quoted Herrera as 'the study's first author, the trial's lead investigator and City of Hope chief of the Division of Lymphoma' re: Nivolumab-AVD Hodgkin lymphoma trial
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →x.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 14 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- BA
Princeton University (summa cum laude)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cityofhope.org ↗ - MD
Harvard Medical School
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cityofhope.org ↗ - Internal Medicine Residency
Brigham and Women's Hospital
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cityofhope.org ↗ - Hematology-Oncology Fellowship
Dana-Farber Cancer Institute/Massachusetts General Hospital
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cityofhope.org ↗ - Board Certified
American Board of Internal Medicine - Hematology
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →healthgrades.com ↗ - Board Certified
American Board of Internal Medicine - Medical Oncology
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →healthgrades.com ↗
Editorial & leadership roles
journal and society appointments- Principal investigator on 40+ clinical trials of novel Hodgkin/non-Hodgkin lymphoma therapies
including 17 investigator-initiated trials
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cityofhope.org ↗
Awards & honors
honors on the public record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cityofhope.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cityofhope.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cityofhope.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cityofhope.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cityofhope.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cityofhope.org ↗
Media & interviews
press, podcasts and appearances- Meet Hematologist Alex F. Herrera
M.D. (City of Hope video profile)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onclive.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →chadinabhan.com ↗
- Passion Behind the Practice: Alex Herrera
MD (City of Hope community feature)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cancercenter.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Sumanta Pal, MD
City of Hope National Medical Center
Joanne Mortimer, MD
City of Hope National Medical Center
Vinod Pullarkat, MD
City of Hope National Medical Center
Tanya Dorff, MD
City of Hope National Medical Center
Joseph Antin, MD
Boston University
Scott Kaufmann, MD
Mayo Clinic College of Medicine
Jeffrey Miller, MD
University of Minnesota Medical School
Ruben Mesa, MD
Atrium Health Wake Forest Baptist Comprehensive Cancer Center